Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free ALLO Stock Alerts

Allogene Therapeutics (ALLO) Financials

Allogene Therapeutics logo
$2.28 +0.01 (+0.44%)
Closing price 04:00 PM Eastern
Extended Trading
$2.31 +0.03 (+1.14%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Allogene Therapeutics

Annual Income Statements for Allogene Therapeutics

This table shows Allogene Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -212 -185 -316 -182 -340 -327 -258 -191
Consolidated Net Income / (Loss)		 -212 -185 -316 -182 -340 -327 -258 -191
Net Income / (Loss) Continuing Operations		 -212 -185 -316 -182 -340 -327 -258 -191
Total Pre-Tax Income 		-212 -185 -316 -182 -340 -327 -257 -191
Total Operating Income		 -193 -202 -258 -180 -336 -328 -273 -209
Total Gross Profit		 0.00 0.00 0.00 114 0.16 0.10 0.02 0.00
Total Revenue		 0.00 0.00 0.00 114 0.16 0.10 0.02 0.00
Operating Revenue		 - 0.00 0.00 114 0.16 0.10 0.02 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 193 202 258 294 336 328 273 209
Selling, General & Admin Expense		 41 57 65 74 79 72 65 57
Research & Development Expense		 152 145 193 220 256 243 192 150
Impairment Charge		 - - - 0.00 0.00 13 16 2.38
Total Other Income / (Expense), net		 -19 17 -58 -1.86 -4.88 0.47 16 18
Interest Expense		 3.36 - - - - 0.00 0.18 1.08
Interest & Investment Income		 - - 9.16 1.71 4.57 18 20 19
Other Income / (Expense), net		 -15 17 -67 -3.57 -9.44 -18 -3.92 0.22
Income Tax Expense		 -0.12 -0.33 - - - 0.00 0.44 0.00
Basic Earnings per Share		 ($7.31) ($1.83) ($2.63) ($1.34) ($2.38) ($2.09) ($1.32) ($0.87)
Weighted Average Basic Shares Outstanding		 28.95M 101.06M 120.37M 135.82M 143.15M 156.93M 194.81M 220.62M
Diluted Earnings per Share		 ($7.31) ($1.83) ($2.63) ($1.34) ($2.38) ($2.09) ($1.32) ($0.87)
Weighted Average Diluted Shares Outstanding		 28.95M 101.06M 120.37M 135.82M 143.15M 156.93M 194.81M 220.62M
Weighted Average Basic & Diluted Shares Outstanding		 28.95M 101.06M 120.37M 142.75M 144.50M 169.09M 217.26M 243.78M
Cash Dividends to Common per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00

Quarterly Income Statements for Allogene Therapeutics

This table shows Allogene Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -79 -62 -86 -65 -66 -66 -60 -60 -51 -41 -39
Consolidated Net Income / (Loss)		 -79 -62 -86 -65 -66 -66 -60 -60 -51 -41 -39
Net Income / (Loss) Continuing Operations		 -79 -62 -86 -65 -66 -66 -60 -60 -51 -41 -39
Total Pre-Tax Income 		-79 -62 -86 -65 -66 -66 -59 -60 -51 -41 -39
Total Operating Income		 -81 -63 -85 -70 -71 -72 -60 -65 -57 -45 -42
Total Operating Expenses		 81 63 85 70 71 72 60 65 57 45 42
Selling, General & Admin Expense		 19 17 17 17 16 16 16 15 14 14 14
Research & Development Expense		 62 46 55 52 50 45 45 50 40 31 29
Total Other Income / (Expense), net		 1.31 0.71 -0.67 4.50 5.07 5.48 0.99 5.46 5.88 3.50 3.59
Interest Expense		 - - - 0.00 0.00 0.10 - 0.15 0.27 0.34 0.31
Interest & Investment Income		 3.78 6.21 - 5.43 4.99 6.71 - 5.52 6.19 3.93 3.66
Other Income / (Expense), net		 -2.47 -5.50 -8.99 -0.93 0.09 -1.12 -7.39 0.09 -0.04 -0.08 0.25
Basic Earnings per Share		 ($0.54) ($0.37) ($0.49) ($0.38) ($0.35) ($0.32) ($0.27) ($0.28) ($0.23) ($0.19) ($0.17)
Weighted Average Basic Shares Outstanding		 146.80M 167.65M 156.93M 169.13M 190.03M 209.19M 194.81M 215.36M 218.93M 222.04M 220.62M
Diluted Earnings per Share		 ($0.54) ($0.37) ($0.49) ($0.38) ($0.35) ($0.32) ($0.27) ($0.28) ($0.23) ($0.19) ($0.17)
Weighted Average Diluted Shares Outstanding		 146.80M 167.65M 156.93M 169.13M 190.03M 209.19M 194.81M 215.36M 218.93M 222.04M 220.62M
Weighted Average Basic & Diluted Shares Outstanding		 167.63M 168.28M 169.09M 170.85M 209.11M 209.67M 217.26M 218.73M 221.88M 224.73M 243.78M

Annual Cash Flow Statements for Allogene Therapeutics

This table details how cash moves in and out of Allogene Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 94 86 13 -9.19 -111 21 -7.94 -24
Net Cash From Operating Activities		 -45 -137 -115 -185 -221 -238 -200 -149
Net Cash From Continuing Operating Activities		 -45 -137 -115 -185 -221 -238 -200 -149
Net Income / (Loss) Continuing Operations		 -212 -185 -316 -182 -340 -327 -258 -191
Consolidated Net Income / (Loss)		 -212 -185 -316 -182 -340 -327 -258 -191
Depreciation Expense		 1.05 4.42 7.44 10 14 14 14 12
Non-Cash Adjustments To Reconcile Net Income		 150 49 140 19 102 91 62 33
Changes in Operating Assets and Liabilities, net		 12 -6.88 54 -32 3.90 -15 -18 -3.37
Net Cash From Investing Activities		 -633 164 -505 164 106 163 76 96
Net Cash From Continuing Investing Activities		 -633 164 -505 164 106 163 76 96
Purchase of Property, Plant & Equipment		 -5.33 -51 -66 -21 -5.19 -1.52 -0.69 -0.39
Purchase of Investments		 -649 -253 -1,038 -526 -248 -439 -361 -138
Sale and/or Maturity of Investments		 22 473 598 728 359 603 438 234
Net Cash From Financing Activities		 771 59 634 12 2.95 96 117 30
Net Cash From Continuing Financing Activities		 771 59 634 12 2.95 96 117 30
Issuance of Common Equity		 344 59 634 12 2.95 96 114 23
Other Financing Activities, net		 11 - - - - 0.00 2.28 6.91

Quarterly Cash Flow Statements for Allogene Therapeutics

This table details how cash moves in and out of Allogene Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 45 -86 14 -32 120 -119 24 -33 9.88 -15 14
Net Cash From Operating Activities		 -62 -56 -54 -56 -64 -44 -37 -53 -39 -30 -28
Net Cash From Continuing Operating Activities		 -62 -56 -54 -56 -64 -44 -37 -53 -39 -30 -28
Net Income / (Loss) Continuing Operations		 -79 -62 -86 -65 -66 -66 -60 -60 -51 -41 -39
Consolidated Net Income / (Loss)		 -79 -62 -86 -65 -66 -66 -60 -60 -51 -41 -39
Depreciation Expense		 3.64 3.57 3.48 3.56 3.64 3.21 3.23 3.10 3.11 3.10 3.06
Non-Cash Adjustments To Reconcile Net Income		 18 22 28 9.99 16 23 13 10 9.12 6.91 6.47
Changes in Operating Assets and Liabilities, net		 -4.36 -19 0.93 -4.44 -17 -4.35 7.05 -6.46 -0.31 1.71 1.69
Net Cash From Investing Activities		 17 -34 67 22 75 -76 55 6.18 44 12 34
Net Cash From Continuing Investing Activities		 17 -34 67 22 75 -76 55 6.18 44 12 34
Purchase of Investments		 -135 -199 -69 -81 -43 -191 -47 -50 -9.92 -50 -28
Sale and/or Maturity of Investments		 153 165 136 103 117 115 102 57 54 62 62
Net Cash From Financing Activities		 90 4.29 0.16 1.65 109 0.68 5.74 14 5.07 3.24 7.86
Net Cash From Continuing Financing Activities		 90 4.29 0.16 1.65 109 0.68 5.74 14 5.07 3.24 7.86
Issuance of Common Equity		 90 4.29 0.16 1.65 106 0.68 5.74 11 1.51 3.24 7.86

Annual Balance Sheets for Allogene Therapeutics

This table presents Allogene Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 774 718 1,228 1,051 822 643 549 416
Total Current Assets		 468 545 845 471 529 459 303 258
Cash & Equivalents		 92 175 183 173 62 83 75 52
Short-Term Investments		 367 355 645 284 455 366 217 199
Prepaid Expenses		 8.60 14 17 14 12 10 11 7.54
Plant, Property, & Equipment, net		 8.60 56 119 123 113 99 86 73
Total Noncurrent Assets		 297 117 264 457 180 84 159 85
Long-Term Investments		 262 63 208 382 76 3.65 81 8.04
Other Noncurrent Operating Assets		 35 53 56 74 103 81 79 77
Total Liabilities & Shareholders' Equity		 774 718 1,228 1,051 822 643 549 416
Total Liabilities		 71 89 148 126 155 131 127 123
Total Current Liabilities		 29 33 94 48 54 37 36 33
Accounts Payable		 12 9.25 10 10 14 5.90 5.39 4.27
Accrued Expenses		 17 24 45 37 40 31 30 28
Total Noncurrent Liabilities		 41 56 54 78 101 94 91 91
Other Noncurrent Operating Liabilities		 41 56 54 78 101 94 91 91
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 703 629 1,080 925 667 512 422 293
Total Preferred & Common Equity		 703 629 1,080 925 667 512 422 293
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 703 629 1,080 925 667 512 422 293
Common Stock		 914 1,024 1,726 1,822 1,912 2,075 2,242 2,303
Retained Earnings		 -212 -396 -646 -895 -1,235 -1,562 -1,820 -2,011
Accumulated Other Comprehensive Income / (Loss)		 0.31 1.15 0.27 -2.57 -9.93 -0.96 -0.09 0.27

Quarterly Balance Sheets for Allogene Therapeutics

This table presents Allogene Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 888 747 771 712 586 647 589 508 471 440
Total Current Assets		 569 481 502 473 395 457 304 292 283 261
Cash & Equivalents		 74 110 155 69 51 171 51 42 52 38
Short-Term Investments		 478 361 337 396 334 274 240 238 221 214
Prepaid Expenses		 17 10 10 7.95 11 12 13 12 9.54 8.53
Plant, Property, & Equipment, net		 114 110 106 103 96 92 89 83 79 76
Total Noncurrent Assets		 204 156 162 136 95 98 196 133 109 103
Long-Term Investments		 99 54 62 38 15 1.13 112 56 30 25
Other Noncurrent Operating Assets		 105 102 100 99 80 97 84 78 80 78
Total Liabilities & Shareholders' Equity		 888 747 771 712 586 647 589 508 471 440
Total Liabilities		 148 155 148 129 125 132 125 123 126 124
Total Current Liabilities		 49 60 55 38 31 37 33 30 32 32
Accounts Payable		 11 15 10 6.21 5.78 13 5.51 5.06 4.85 3.70
Accrued Expenses		 37 45 44 31 25 24 27 25 27 28
Total Noncurrent Liabilities		 99 95 93 92 94 95 93 93 94 93
Other Noncurrent Operating Liabilities		 99 95 93 92 94 95 93 93 94 93
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 740 592 623 583 461 515 464 385 345 315
Total Preferred & Common Equity		 740 592 623 583 461 515 464 385 345 315
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 740 592 623 583 461 515 464 385 345 315
Common Stock		 1,894 1,933 2,039 2,060 2,090 2,209 2,223 2,265 2,275 2,287
Retained Earnings		 -1,141 -1,335 -1,413 -1,474 -1,627 -1,694 -1,760 -1,880 -1,930 -1,972
Accumulated Other Comprehensive Income / (Loss)		 -13 -5.93 -3.85 -2.41 -0.93 -0.78 0.16 0.04 -0.05 0.24

Annual Metrics And Ratios for Allogene Therapeutics

This table displays calculated financial ratios and metrics derived from Allogene Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 121,482,671.00 121,902,101.00 140,280,152.00 142,515,938.00 - - - 224,730,144.00
DEI Adjusted Shares Outstanding		 121,482,671.00 121,902,101.00 140,280,152.00 142,515,938.00 - - - 224,730,144.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.74 -1.51 -2.26 -1.28 - - - -0.85
Growth Metrics		 - - - - - - - -
Profitability Metrics		 - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -135 -141 -181 -126 -235 -229 -191 -147
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -44.79% -45.30% -50.09%
Earnings before Interest and Taxes (EBIT)		 -208 -185 -326 -184 -345 -346 -277 -209
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -203 -180 -318 -173 -331 -331 -263 -197
Valuation Ratios		 - - - - - - - -
Leverage & Solvency		 - - - - - - - -
Liquidity Ratios		 - - - - - - - -
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -195 -189 -168 -222 -216 -180 -132
Efficiency Ratios		 - - - - - - - -
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -18 35 44 86 73 60 49 34
Increase / (Decrease) in Invested Capital		 0.00 53 8.49 42 -12 -13 -11 -15
Book Value per Share		 $5.79 $5.16 $7.70 $6.49 $4.62 $3.04 $2.01 $1.30
Tangible Book Value per Share		 $5.78 $5.16 $7.70 $6.49 $4.62 $3.04 $2.01 $1.30
Total Capital		 703 629 1,080 925 667 512 422 293
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -721 -594 -1,036 -840 -594 -452 -373 -258
Capital Expenditures (CapEx)		 5.33 51 66 21 5.19 1.52 0.69 0.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -21 -19 -77 -34 -42 -27 -25 -25
Debt-free Net Working Capital (DFNWC)		 439 511 751 423 475 422 268 225
Net Working Capital (NWC)		 439 511 751 423 475 422 268 225
Net Nonoperating Expense (NNE)		 77 43 136 56 106 98 66 44
Net Nonoperating Obligations (NNO)		 -721 -594 -1,036 -840 -594 -452 -373 -258
Total Depreciation and Amortization (D&A)		 4.86 5.03 7.59 10 14 14 14 12
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 ($7.31) ($1.83) ($2.08) ($1.89) $0.00 ($2.09) ($1.32) ($0.87)
Adjusted Weighted Average Basic Shares Outstanding		 121.48M 124.91M 140.65M 135.82M 0.00 156.93M 194.81M 220.62M
Adjusted Diluted Earnings per Share		 ($7.31) ($1.83) ($2.08) ($1.89) $0.00 ($2.09) ($1.32) ($0.87)
Adjusted Weighted Average Diluted Shares Outstanding		 121.48M 124.91M 140.65M 135.82M 0.00 156.93M 194.81M 220.62M
Adjusted Basic & Diluted Earnings per Share		 ($7.31) ($1.83) ($2.08) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 28.95M 101.06M 120.37M 142.75M 0.00 169.09M 217.26M 243.78M
Normalized Net Operating Profit after Tax (NOPAT)		 -135 -141 -181 -126 -235 -220 -180 -145
Debt Service Ratios		 - - - - - - - -
Payout Ratios		 - - - - - - - -

Quarterly Metrics And Ratios for Allogene Therapeutics

This table displays calculated financial ratios and metrics derived from Allogene Therapeutics' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - 217,264,738.00 218,730,809.00 221,881,029.00 224,730,144.00
DEI Adjusted Shares Outstanding		 - - - - - - - 217,264,738.00 218,730,809.00 221,881,029.00 224,730,144.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - -0.27 -0.23 -0.19 -0.17
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -56 -44 -60 -49 -50 -50 -42 -46 -40 -31 -30
Return On Investment Capital (ROIC_SIMPLE)		 - - -11.63% - - - -10.03% -11.84% -11.54% -9.97% -10.15%
Earnings before Interest and Taxes (EBIT)		 -83 -68 -94 -65 -71 -73 -68 -65 -57 -45 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -79 -65 -91 -61 -68 -70 -65 -62 -54 -42 -39
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 -36 -46 -43 -51 -31 -31 -34 -12 -9.26 -15
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 68 80 60 61 69 60 49 50 42 38 34
Increase / (Decrease) in Invested Capital		 -32 -8.52 -13 -5.74 0.83 -20 -11 -12 -27 -22 -15
Book Value per Share		 $4.27 $3.48 $3.04 $2.73 $3.01 $2.22 $2.01 $1.77 $1.58 $1.42 $1.30
Tangible Book Value per Share		 $4.27 $3.48 $3.04 $2.73 $3.01 $2.22 $2.01 $1.77 $1.58 $1.42 $1.30
Total Capital		 623 583 512 461 515 464 422 385 345 315 293
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -554 -503 -452 -400 -446 -403 -373 -336 -303 -277 -258
Capital Expenditures (CapEx)		 0.29 0.01 0.18 0.01 0.00 0.43 0.26 0.10 0.04 0.24 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -45 -30 -27 -20 -25 -20 -25 -18 -22 -23 -25
Debt-free Net Working Capital (DFNWC)		 447 436 422 364 420 272 268 262 251 229 225
Net Working Capital (NWC)		 447 436 422 364 420 272 268 262 251 229 225
Net Nonoperating Expense (NNE)		 23 18 26 16 16 16 18 14 11 9.97 9.13
Net Nonoperating Obligations (NNO)		 -554 -503 -452 -400 -446 -403 -373 -336 -303 -277 -258
Total Depreciation and Amortization (D&A)		 3.64 3.57 3.48 3.56 3.64 3.21 3.23 3.10 3.11 3.10 3.06
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.53) ($0.37) ($0.49) ($0.38) ($0.35) ($0.32) ($0.27) ($0.28) ($0.23) ($0.19) ($0.17)
Adjusted Weighted Average Basic Shares Outstanding		 146.80M 167.65M 156.93M 169.13M 190.03M 209.19M 194.81M 215.36M 218.93M 222.04M 220.62M
Adjusted Diluted Earnings per Share		 ($0.53) ($0.37) ($0.49) ($0.38) ($0.35) ($0.32) ($0.27) ($0.28) ($0.23) ($0.19) ($0.17)
Adjusted Weighted Average Diluted Shares Outstanding		 146.80M 167.65M 156.93M 169.13M 190.03M 209.19M 194.81M 215.36M 218.93M 222.04M 220.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 167.63M 168.28M 169.09M 170.85M 209.11M 209.67M 217.26M 218.73M 221.88M 224.73M 243.78M
Normalized Net Operating Profit after Tax (NOPAT)		 -56 -44 -60 -49 -47 -43 -42 -46 -38 -31 -30
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Allogene Therapeutics, Inc. (ALLO) has not reported revenue in most quarterly results in the period analyzed. The company continues to burn cash due to high R&D and SG&A expenses, but liquidity improved in 2025 thanks to equity financings and asset sales.

  • Equity financings in 2025 added about $31 million in cash across quarters (Q1: $10.66M; Q2: $15.14M; Q3: $3.24M; Q4: $7.86M), boosting near-term liquidity.
  • Net cash from financing activities was positive in several quarters in 2025, reflecting those equity raises and related financing activity.
  • Significant cash inflows from sale and maturity of investments occurred in Q3 and Q4 2025 (roughly $61.9M in each quarter), providing liquidity headroom.
  • Net loss narrowed over 2025 (Q1: -$59.7M to Q4: -$38.8M), suggesting improvement in the burn rate though profitability remains out of reach.
  • Operating revenue remained negligible in most quarters, indicating continued dependence on financing and non-operating cash flows.
  • R&D and SG&A expenses remained the primary cash burn drivers (Q4 2025: RD $28.6M; SG&A $13.8M), reflecting ongoing development costs.
  • Net cash from operating activities stayed negative in every quarter, signaling ongoing cash burn from core operations.
  • Net income attributable to common shareholders remained negative in all quarters (Q4 2025: -$38.8M; Q3 2025: -$41.4M), underscoring continued losses.
  • Investing activities showed sizable cash outflows (e.g., large purchases of investments) and limited offsetting inflows in some quarters, contributing to cash usage.
  • Equity issuances create dilution risk for existing shareholders, even as they fund operations.
05/09/26 12:00 AM ETAI Generated. May Contain Errors.

Allogene Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Allogene Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

In the past 7 years, Allogene Therapeutics' net income has ranged from -$340.41 million in 2022 to -$182.05 million in 2021, and is currently -$190.89 million as of their latest financial filing in 2025. See where experts think Allogene Therapeutics is headed by visiting Allogene Therapeutics' forecast page.

Allogene Therapeutics' total operating income in 2025 was -$209.32 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $209.32 million

Over the last 7 years, Allogene Therapeutics' total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

Allogene Therapeutics' total liabilities were at $123.36 million at the end of 2025, a 2.5% decrease from 2024, and a 74.5% increase since 2018.

In the past 7 years, Allogene Therapeutics' cash and equivalents has ranged from $51.69 million in 2025 to $183.35 million in 2020, and is currently $51.69 million as of their latest financial filing in 2025.

Over the last 7 years, Allogene Therapeutics' book value per share changed from 5.79 in 2018 to 1.30 in 2025, a change of -77.5%.


Related Companies

Financial statements for NASDAQ:ALLO last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
Batten down the hatches – Project Tengu is coming
Starting June 16, This AI Lab Could Take Off Dramatically Time magazine recently named this lab "the most d...
Chaikin Analytics | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $25 trillion opportunity unfolding now
Wall Street is calling it a 25 trillion revolution - and it's already underway. Driven by a breakthrough techn...
The Oxford Club | Sponsoredtc pixel
Why Elon just bought a power plant (Ticker inside)
Elon Musk is burning nearly $1 billion a month because he cannot power the world's largest supercomputer witho...
Behind the Markets | Sponsoredtc pixel